Philip Seeman, MD, PhD Toronto, Ontario
Re: "Cades Disease" and Beyond

Dear Editor:
Dr Ghaemi and colleagues are convinced that bipolar disorder (BD) is greatly underdiagnosed (1) .
Recently, I have seen 2 cases in which patients were diagnosed and treated for BD after being treated for other diagnosed disorders. In each case, their conditions worsened.
Case Report 1
Mrs A is married, in early middle age, and has 2 teenaged children. She was admitted to hospital and diagnosed with unipolar depression, together with some long-standing personality and family problems. She responded poorly to treatment, was discharged with mild improvement, and readmitted soon after. On readmission, her treating psychiatrist undertook a detailed review of her history, rediagnosed her with BD, and treated her with divalproex. She was told the diagnosis. She seemed to improve rapidly, and was discharged home. In follow-up for the next few months, her self-report was very good and she was very pleased with the psychiatrist for taking the time to reassess her and find the "correct" diagnosis. Then, one of her daughters attempted suicide, giving as a reason the fact that her mother had no time for her because she was spending all her time on a BD Internet chat line. After this, the patient was no longer pleased with her psychiatrist and was lost to follow-up.
Case Report 2
When she presented for treatment, Mrs B, also middle-aged, was in a second, quite supportive marriage. She had a history of an abusive first marriage and severe dysfunction during her childhood. She had left that marriage, taken a college course that interested her, obtained a diploma, and obtained appropriate work.
She quickly found her work too stressful, largely because it reminded her of things in her past that caused a recurrence of posttraumatic stress disorder (PTSD) symptoms. When she presented for treatment, she was diagnosed with unipolar depression, generalized anxiety disorder, and subsyndromal PTSD symptoms. She did not respond well to treatment and was unable to return to work after a period of many months. She and her husband then decided to seek assessment and treatment from a different psychiatrist, with the original psychiatrist's agreement. She was diagnosed with BD, started on divalproex, and discharged. A few months later, she presented to her original psychiatrist. She said that on divalproex she had felt "totally flat" and refused to live that way. She had therefore discontinued it, and her former symptoms all promptly recurred. Her psychiatrist told her that he did not agree with the diagnosis of BD but had no new treatment to offer her, other than a trial of different antidepressant medication. She accepted that and also learned to accept that she was not able to work in her chosen field. She subsequently improved moderately.
I suggest that there may be as much danger in overdiagnosing as in underdiagnosing BD.
and spent a great deal of time on Internet chat sites, to the dismay of her family. This activity does not speak at all to the question of whether the BD diagnosis was accurate. In the second case, the patient was diagnosed with BD and did not feel that valproate helped her. Again, this fact by itself does not prove that the BD diagnosis was inaccurate. Indeed, response to a single mood stabilizer occurs, at best, in only one-third of patients with BD (1). Many patients with BD who respond to lithium do not respond to valproate, and vice versa (2) . The correspondent's complaint in the second case appears chiefly to be about the treatments for BD and not about the diagnosis itself. It is our sense that many clinicians hesitate to diagnose BD because of their dissatisfaction with available treatments. This is a practical problem; hopefully, it will be less of an issue as newer, more tolerable mood stabilizers are developed. However, this practical problem has nothing to do with the empirical fact of whether someone meets or does not meet criteria for BD, based on an accurate and complete examination of symptoms and history. It is also interesting that both patients apparently responded poorly to standard unipolar treatments (antidepressants), yet the author does not conclude that this argues against the unipolar diagnosis. In fact, poor outcomes with antidepressants are quite common in the histories of patients with BD, as we reviewed in our paper.
We therefore just do not see how these 2 cases at all justify a claim for overdiagnosis of BD. We agree that there are cases in which BD is erroneously diagnosed. Possibly, the vague use of the term "mood swings" may lead to a mistaken diagnosis of BD in a person with a personality disorder or some other condition. However, in our paper, we described much more specific criteria than vague mood swings.
Importantly, to our knowledge there is absolutely no published or presented empirical evidence supporting the idea that BD is overdiagnosed. There is, as we reviewed in our paper, plenty of evidence to the contrary-that BD has been and remains underdiagnosed. Even if occasional cases of erroneous diagnosis were found, it would be necessary to show that such cases are more frequent than the misdiagnosis of BD before one could claim that BD overall is overdiagnosed. It is a simple fact of scientific method, highlighted by the evidence-based medicine literature (3) , that case reports do not refute empirical studies. There is no appreciable evidence that BD is overdiagnosed. Quetiapine is as effective as haloperidol and chlorpromazine in relieving both the positive and negative symptoms of schizophrenia at dosages ranging from 150 to 750 mg daily (1-3).
In premarketing placebo-controlled trials, quetiapine use has been associated with a dosage-related decrease in total and free thyroxin (T4), with transient leukopenia, and with an elevation from baseline in cholesterol, triglyceride, and hepatic transaminases (4).
Case Report
MM is a 41-year-old woman diagnosed with schizophrenia at age 22 years. While taking chlorpromazine 600 mg daily, she was well (that is, her schizophrenia was episodic, with no interepisode residual symptoms) and functioned independently in the community for over 18 years.
Nonadherence to treatment preceded the recurrence of positive symptoms, social withdrawal, and poor personal hygiene, which led to her readmission to a psychiatric hospital for over 7 months in 2001. Pharmacotherapy with optimal dosages of olanzapine and risperidone did not appreciably improve her target symptoms. After haloperidol 10 mg daily was commenced, improvement in the target symptoms was evident, and she was discharged home. She was readmitted 7 weeks later because she had not adhered to follow-up plans and had discontinued her medication without medical advice. After she developed extrapyramidal side effects (EPSEs), haloperidol was replaced by quetiapine at 150 mg daily, titrated to 600 mg daily over 4 weeks, and the EPSEs resolved. Her pre-quetiapine white blood cell count (WBC) was 6.6, and her absolute neutrophil count was 4.0. Four weeks later, a repeat complete blood count revealed leukopenia of 1.7 and absolute neutropenia of 0.3. The following day, the leukocyte and absolute neutrophils counts were 2.0 and 0.2, respectively. MM agreed to the substitution of chlorpromazine for quetiapine. She had no clinical evidence of infection, her vital signs were normal, and she had no known prior or contemporanious medical history that might explain the laboratory findings. At quetiapine 450 mg daily, 300 mg daily, 150 mg daily, and 1 week after discontinuation, the respective WBC and absolute neutrophil counts were 2.4 and 0.4, 4.8 and 2.8, 6.2 and 4.6, 6.4 and 4.7 (within normal limits). MM refused a rechallenge with quetiapine.
This patient experienced a quetiapineassociated, dosage-related, reversible leucopenia. Hematological abnormalities
